Xencor (XNCR) reported a Q4 net loss of $0.62 per diluted share, wider than its loss of $0.43 year earlier.
Analysts surveyed by FactSet expected a loss of $0.78.
Revenue for the quarter ended Dec. 31 was $52.8 million, compared with $51 million a year earlier.
Analysts surveyed by FactSet expected $20.4 million.
The clinical-stage biopharmaceutical company said it expects to end 2025 with cash, cash equivalents and marketable debt securities in a range of $535 million to $585 million, and to have cash to fund research, development programs and operations into 2028.
Price: 14.81, Change: +0.43, Percent Change: +2.99
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.